Dergiler / Okmeydanı Tıp Dergisi / 2018 / Cilt: 34 - Sayı: 2

Platelet-to-Lymphocyte Ratio is an Independent Prognostic Factor in Clinically Non-Metastatic Renal Cell Carcinoma

Klinik Non-Metastatik Renal Hücreli Kanserde Trombosit/ Lenfosit Oranı Bağımsız Prognostik Bir Faktördür

Sayfa
109–115
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

PLR may provide a significant adjunct for clinical trial design and risk stratifying patients for localized RCC.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: We aimed to investigate the prognostic significance of the preoperative platelet-to-lymphocyte ratio (PLR) in a cohort of clinically non-metastatic renal cell carcinoma (RCC).
📊
Temel Bulgular & Veri:Material and Methods: We evaluated a retrospective analysis of 298 patients who underwent radical or partial nephrectomy for RCC between 2006 and 2015.
💡
Sonuç & Katkı:PLR may provide a significant adjunct for clinical trial design and risk stratifying patients for localized RCC.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:2006 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: We aimed to investigate the prognostic significance of the preoperative platelet-to-lymphocyte ratio (PLR) in a cohort of clinically non-metastatic renal cell carcinoma (RCC). Material and Methods: We evaluated a retrospective analysis of 298 patients who underwent radical or partial nephrectomy for RCC between 2006 and 2015. The optimal cutoff value for the PLR was calculated using receiver operating curce (ROC) analysis. The prognostic value of PLR was determined by Kaplan-Meier curve, univariable and multivariable Cox regression models. Results: The optimal cut-off level was 200 (AUC=0.715; sensitivity, 52.4%; specificity, 90.6%) for PLR by ROC curve analysis and elevated PLR was significantly correlated with worse cancer-specific survival (CSS). Multivariable analysis showed that elevated PLR was an independent risk factor for CSS (HR, 3.460; 95% CI, 1.691-7.081; p=0.001). A high PLR was also significantly correlated with aggressive tumor behaviors. Subgroup analysis revealed significant associations of the elevated PLR on CSS for both clear cell and non-clear cell RCC types (p<0.001). Conclusion: The PLR is an independent prognostic factor for CSS after treatment with curative intent for clinically localized clear cell and non-clear cell RCC. PLR may provide a significant adjunct for clinical trial design and risk stratifying patients for localized RCC.

Abstract

Amaç: Operasyon öncesi trombosit/lenfosit oranı (TLO)’nın klinik non-metastatik renal hücreli kanser (RHK)’de prognostik öneminin araştırılması planlandı. Gereç ve Yöntem: RHK nedeniyle 2006 ve 2015 yılları arasında radikal veya parsiyel nefrektomi geçiren 298 hastanın retrospektif analizi yapıldı. TLO için optimal kestirim değeri “receiver operating curve” (ROC) analizi ile hesaplandı. TLO’nun prognostik önemi; Kaplan-Meier eğrileri, tek değişkenli ve çok değişkenli Cox regresyon modelleri ile değerlendirildi. Bulgular: TLO için ROC analizi ile optimal kestirim noktası 200 (AUC=0.715; sensitivite, %52,4; spesifite, %90,6) idi ve yükselen TLO daha kötü kanser spesifik sağkalım (KSS) ile anlamlı olarak ilişkili bulundu. Çok değişkenli analiz ile yükselen TLO’nun KSS için bağımsız bir risk faktörü olduğu gösterildi (HR, 3,460; 95% CI, 1,691-7.081; p=0,001). Ayrıca yüksek TLO’nun agresif tümör davranışı ile anlamlı ilişkisi olduğu gösterildi. Altgrup analizine göre yükselen TLO’nun hem clear cell hem de non-clear cell RHK’de KSS ile anlamlı ilişkisi saptandı. Sonuç: Klinik lokalize clear cell ve non-clear cell RHK’de küratif amaçlı yapılan tedaviler sonrası TLO, KSS için bağımsız prognostik bir faktördür. TLO, lokalize RHK ile ilişkili klinik çalışmaların dizaynında ve risk sınıflamasında anlamlı bir katkı sağlayabilir.

🔖

Bu Makaleye Atıf Yap

CANAT, L., AGALAROV, S., AKKAŞ, F., ATALAY, H. A., ALKAN, İ., ÇAKIR, S. S., ALTUNRENDE, F., ÖTÜNÇTEMUR, A. (2018). Platelet-to-Lymphocyte Ratio is an Independent Prognostic Factor in Clinically Non-Metastatic Renal Cell Carcinoma. Okmeydanı Tıp Dergisi, Cilt: 34 - Sayı: 2, 109–115. https://ajindex.com/articles/291628

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612-24.
  2. Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU Int. 2012;110: E553.
  3. Chen DYT, Uzzo RG, Viterbo R. Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death. World J Urol. 2014;32:607-13.
  4. Ficarra V, Righetti R, Pilloni S,D’amico A, Maffei N, Novella Get al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol. 2002;41:190-8.
  5. Bedke J, Laske K, Feyerabend S, Gouttefangeas C, Dröge A, Hennelotter J, et al. Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur Urol. 2012;11:e76-ea.
  6. Deng Q, He B, Liu X, Yue J, Ying H, Pan Y, et al. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med. 2015;13:66.
  7. Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/ monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135(2):362-70.
  8. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, et al.Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012;12:399.
  9. Dirican A, Kucukzeybek Y, Somali I, Erten C, Demir L, Can A, et al. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma. J BUON. 2013;18:413-9
  10. Dirican A, Kucukzeybek Y, Erten C, Somali I, Demir L, Can A, et al. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev. 2013